Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease - PubMed (original) (raw)

Review

Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease

L Buée et al. Brain Pathol. 1999 Oct.

Abstract

Neurodegenerative disorders referred to as tauopathies have cellular hyperphosphorylated tau protein aggregates in the absence of amyloid deposits. Comparative biochemistry of tau aggregates shows that they differ in both phosphorylation and content of tau isoforms. The six tau isoforms found in human brain contain either three (3R) or four microtubule-binding domains (4R). In Alzheimer's disease, all six tau isoforms are abnormally phosphorylated and aggregate into paired helical filaments. They are detected by immunoblotting as a major tau triplet (tau55, 64 and 69). In corticobasal degeneration and progressive supranuclear palsy, only 4R-tau isoforms aggregate into twisted and straight filaments respectively. They appear as a major tau doublet (tau64 and 69). Finally, in Pick's disease, only 3R-tau isoforms aggregate into random coiled filaments. They are characterized by another major tau doublet (tau55 and 64). These differences in tau isoforms may be related to either the degeneration of particular cell populations in a given disorder or aberrant cell trafficking of particular tau isoforms. Finally, recent findings provide a direct link between a genetic defect in tau and its abnormal aggregation into filaments in fronto-temporal dementia with Parkinsonism linked to chromosome 17, demonstrating that tau aggregation is sufficient for nerve cell degeneration. Thus, tau mutations and polymorphisms may also be instrumental in many neurodegenerative disorders.

PubMed Disclaimer

References

    1. Auer IA, Schmidt ML, Lee VM, Curry B, Suzuki K, Shin RW, Pentchev PG, Carstea ED, Trojanowski JQ (1995) Paired helical filament tau (PHFtau) in Niemann‐Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol 90: 547–551. - PubMed
    1. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez‐Tur J, Hardy J, Lynch T, Bigio E, Hutton M (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8: 711–715. - PubMed
    1. Bennett P, Bonifati V, Bonuccelli U, Colosimo C, De Mari M, Fabbrini G, Marconi R, Meco G, Nicholl DJ, Stocchi F, Vanacore N, Vieregge P, Williams AC (1998) Direct genetic evidence for involvement of tau in progressive supranuclear palsy. European Study Group on Atypical Parkinsonism Consortium. Neurology 51: 982–985. - PubMed
    1. Bergeron C, Pollanen MS, Weyner L, Lang AE (1997) Cortical degeneration in progressive supranuclear palsy. A comparison with cortico‐basal ganglionic degeneration. J Neuropathol Exp Neurol 56: 726–734. - PubMed
    1. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E (1993) Phosphorylation of Ser(262) strongly reduces binding of tau proteins to microtubules ‐ distinction between PHF‐like immunoreactivity and microtubule binding. Neuron 11: 153–163. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources